We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The RNA Polymerase Inhibitor Corallopyronin A Has a Lower Frequency of Resistance Than Rifampicin in Staphylococcus aureus.
- Authors
Balansky, Jan; Pfarr, Kenneth; Szekat, Christiane; Kehraus, Stefan; Aden, Tilman; Grosse, Miriam; Jansen, Rolf; Hesterkamp, Thomas; Schiefer, Andrea; König, Gabriele M.; Stadler, Marc; Hoerauf, Achim; Bierbaum, Gabriele
- Abstract
Corallopyronin A (CorA) is active against Gram-positive bacteria and targets the switch region of RNA polymerase. Because of the high frequency of mutation (FoM) leading to rifampicin resistance, we determined the CorA FoM in S. aureus using fluctuation analysis at 4 × minimum inhibitory concentration (MIC). Resistant mutants were characterized. S. aureus strains HG001, Mu50, N315, and USA300 had an MIC of 0.25 mg/L. The median FoM for CorA resistance was 1.5 × 10−8, 4.5-fold lower than the median FoM of 6.7 × 10−8 for rifampicin, and was reflected in a 4-fold lower mutation rate for CorA than rifampicin (6 × 10−9 for CorA vs. 2.5 × 10−8 for rifampicin). In CorA-resistant/rifampicin-sensitive strains, the majority of amino acid exchanges were S1127L in RpoB or K334N in RpoC. S. aureus Mu50, a rifampicin-resistant clinical isolate, yielded two further exchanges targeting amino acids L1131 and E1048 of the RpoB subunit. The plating of >1011 cells on agar containing a combination of 4 × MIC of rifampicin and 4 × MIC of CorA did not yield any growth. In conclusion, with proper usage, e.g., in combination therapy and good antibiotic stewardship, CorA is a potential antibiotic for treating S. aureus infections.
- Subjects
RNA polymerases; RIFAMPIN; STAPHYLOCOCCUS aureus; GRAM-positive bacteria; ANTIMICROBIAL stewardship; AMINO acids
- Publication
Antibiotics (2079-6382), 2022, Vol 11, Issue 7, p920
- ISSN
2079-6382
- Publication type
Article
- DOI
10.3390/antibiotics11070920